anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
Kymera · pitchdeck

Kymera | Investor Presentation Deck | 41 slides

41 pages · 4 arc beats · 2 loops

Pitchdeck Download JSON
Unlock

Kymera | Investor Presentation Deck | 41 slides

Kymera · 2023-11
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
— No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.
—

Deck intelligence map

4
coverage by narrative range · generated from this deck JSON
Narrative range 16 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem 2 slides 100% 2/2 slides 100% 2/2 slides · 6 hits
— 0/2 slides
— 0/2 slides
— 0/2 slides
100% 2/2 slides 100% 2/2 slides Solution 2 slides 100% 2/2 slides 100% 2/2 slides · 11 hits
— 0/2 slides
— 0/2 slides
— 0/2 slides
100% 2/2 slides
— 0/2 slides
Traction 10 slides 100% 10/10 slides 100% 10/10 slides · 46 hits
— 0/10 slides
90% 9/10 slides · 15 hits 10% 1/10 slides 100% 10/10 slides 100% 10/10 slides Roadmap 2 slides 100% 2/2 slides 100% 2/2 slides · 6 hits
— 0/2 slides
— 0/2 slides
— 0/2 slides
100% 2/2 slides
— 0/2 slides

Slide inventory

41
every slide · same image gating as the playbook
01
Slide 1
Includes company logo and date.front_matter
Open slide detail
02
other
Open slide detail
03
The slide uses a split-layout with a branding/mission sidebar and a bulleted list of key achievements.summarize
Open slide detailBeat · ProblemLoop · Cost Of Inaction
04
show_traction
Open slide detailBeat · ProblemLoop · Cost Of Inaction
05
TPD = Targeted Protein Degradation. UD = Undrugged, ID = Inadequately drugged.present_solution
Open slide detailBeat · Solution
06
The slide uses a standard pharmaceutical pipeline table format.plan_implementation
Open slide detailBeat · Solution
07
The slide uses an abstract, scientific-looking background, likely representing molecular or biological structures.transition
Open slide detail
08
Includes a biological pathway diagram and a specific 'Degrader Advantage' callout box.present_solution
Open slide detail
09
Includes a mechanism of action diagram, a market data table, and a comparison of current therapy limitations.size_opportunity
Open slide detail
10
show_traction
Open slide detailBeat · TractionLoop · Quick Win Big Bet
11
Includes both a longitudinal line chart of IRAK4 reduction and a grouped bar chart with a summary table for cytokine inhibition.show_traction
Open slide detailBeat · TractionLoop · Quick Win Big Bet
12
Includes PK/PD correlation, IRAK4 levels in PBMC, and skin lesion reduction data.show_traction
Open slide detailBeat · TractionLoop · Quick Win Big Bet
13
The slide displays 12 bar charts representing log2(fold change) for specific genes across individual patients.analyze_data
Open slide detailBeat · TractionLoop · Quick Win Big Bet
14
Includes error bars representing standard error of the mean; data points are plotted over 42 days.analyze_data
Open slide detailBeat · TractionLoop · Quick Win Big Bet
15
The slide includes a disclaimer regarding the non-head-to-head nature of the comparison.compare_peers
Open slide detailBeat · TractionLoop · Quick Win Big Bet
16
Data includes error bars representing standard error of the mean (S.E. of Mean) or 80% confidence intervals.show_traction
Open slide detailBeat · TractionLoop · Quick Win Big Bet
17
The slide includes a disclaimer regarding the non-head-to-head nature of the comparison.compare_peers
Open slide detailBeat · TractionLoop · Quick Win Big Bet
18
The slide highlights a favorable safety profile with no serious adverse events (SAEs) or drug-related infections.analyze_data
Open slide detailBeat · TractionLoop · Quick Win Big Bet
19
Focuses on partnership dynamics and clinical progress.show_traction
Open slide detailBeat · TractionLoop · Quick Win Big Bet
20
Includes clinical trial identifiers and definitions of acronyms in the footer.analyze_data
Open slide detail
21
The slide uses an abstract, scientific-looking background, likely representing molecular or biological structures.transition
Open slide detail
22
Includes a table of prevalence/incidence for various indications and a diagram of the JAK-STAT signaling pathway.present_solution
Open slide detail
23
The slide uses a dual-chart layout to correlate tumor volume reduction with PK/PD profiles.show_traction
Open slide detail
24
The slide uses a process flow diagram to illustrate the dose escalation (0.05 to 0.40 mg/kg) leading to MTD/RP2D expansion into four specific patient cohorts.plan_implementation
Open slide detail
25
The table displays adverse events occurring in 2 or more patients. Data includes patient counts and percentages for both 'All' and 'Related' adverse events.analyze_data
Open slide detail
26
Includes a line chart showing plasma concentration over time and a table summarizing PK parameters (Cmax, AUClast, Vd, CL, t1/2).analyze_data
Open slide detail
27
Data presented as % change from C1D1 Predose. Includes time course line chart and dot plot for maximum degradation.show_traction
Open slide detail
28
Data from a clinical study of KT-333, showing biomarker response across different dose levels (DL1, DL2, DL3).show_traction
Open slide detail
29
Includes ASH logo and specific clinical trial metrics (DL levels, AE types).show_traction
Open slide detail
30
The slide uses a split-layout: left side for clinical data results, right side for strategic positioning.show_traction
Open slide detail
31
transition
Open slide detail
32
Includes a waterfall plot of cell line dependency and a biological process diagram showing the MDM2-p53 feedback loop.present_solution
Open slide detail
33
Includes three dose-response curves and a comparative table of clinical stage and potency metrics.compare_peers
Open slide detail
34
Comparison of KT-253 vs DS-3032 (SMI) across protein levels and tumor volume over time.present_solution
Open slide detail
35
Includes a visual representation of the dose escalation study design and a detailed table of patient baseline characteristics.analyze_data
Open slide detail
36
The slide combines a biological mechanism diagram with clinical trial data (table and line chart) to validate the drug's mechanism of action.show_traction
Open slide detail
37
Swimmer plot showing days on study for three patients, with corresponding CT scan imagery for one patient.show_traction
Open slide detail
38
Clinical trial safety reporting slide.analyze_data
Open slide detail
39
The slide uses a split-layout to contrast technical mechanism/data (left) with strategic market opportunity (right).show_traction
Open slide detail
40
plan_implementation
Open slide detailBeat · Roadmap
41
other
Open slide detailBeat · Roadmap